One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Amyotrophic Lateral Sclerosis Treatment Market

[ 英語タイトル ] Amyotrophic Lateral Sclerosis Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)


Product Code : MDHC0089355
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 117
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Mitsubishi Tanabe Pharma Corporation
- Sun Pharmaceutical Industries Ltd.
- CORESTEM, Inc
- BrainStorm Cell Limited
- Otsuka Pharmaceutical Co., Ltd.
- AB Science
- Ionis Pharmaceuticals
- Biohaven Pharmaceutical
- Biogen
- F.Hoffmann-La Roche AG

[Report Description]

The Amyotrophic Lateral Sclerosis Treatment is expected to register a CAGR of 5.5% during the forecast period. This is attributing the rising prevalence of amyotrophic lateral sclerosis diseases and the growing geriatric population worldwide. As per the Centers for Disease Control and Prevention, in 2016, amyotrophic lateral sclerosis (ALS) is a common neuromuscular disease globally and around 14000-15000 individuals have experienced (ALS) in the United States. In addition, according to the National Institute of Neurological Disorder and Stroke, Sporadic ALS is the most common form type contributed to 90% of cases in the United States and Familial ALS contributed 10%. Thus, these populations are going to promote the demand for treatment of this disorder. Although there is no permanent solution for this disorder, stem cell therapies and medications will prevent complications and decline the disease progression. Moreover, the growing adoption of a sedentary lifestyle will be going to increase the chances of developing this disorder among the aging population which further creates a lucrative opportunity for major players to work for novel therapeutics approaches and treatments. However, less awareness and high costs associated with the treatment may hamper the market to a certain extent.

Key Market Trends

Medications in Amyotrophic Lateral Sclerosis Treatment (ALS) is Estimated to Witness a Healthy Growth in Future.

Medications in amyotrophic lateral sclerosis treatment are estimated to witness healthy growth in the future. Medications such as riluzole and edaravone are the only two drugs that are approved by the Food and Drug Administration (FDA) to treat ALS. In addition, the FDA also approved NeuRx Diaphragm Pacing System wherein implanted electrodes and batteries are used to contract diaphragm in the ALS population. Moreover, medications help in relieving symptoms, spasticity, panic attacks, pain, and depression. Thus, the rising prevalence of ALS diseases worldwide will be going to trigger the demand for these drugs for treatment and thereby drives the segment growth.

Stem cell therapies will also be going to witness a significant growth rate in the forecasted period owing to the increasing demand for novel approaches and advanced therapy options. Furthermore, several initiatives associated with amyotrophic lateral sclerosis treatment will also boost the overall market.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the global Amyotrophic Lateral Sclerosis Treatment due to the rising prevalence of Amyotrophic Lateral Sclerosis diseases, the growing demand for ALS drugs, increasing healthcare expenditure, and well- established healthcare infrastructure, favorable reimbursement policies, and technological advancements. Furthermore, the presence of the geriatric population is more likely to have these disorders. As per the Centers for Disease Control and Prevention (CDC) with Agency for Toxic Substances and Disease Registry (ATSDR) said the majority of the population who are above 50 years more prone to have this disorder and thus expected to fuel the Amyotrophic Lateral Sclerosis Treatment in this region.

Competitive Landscape

The Amyotrophic Lateral Sclerosis Treatment is moderately competitive and consists of several major players. Some of the companies which are playing crucial role in the market studied are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Otsuka Pharmaceutical Co., Ltd., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, and F.Hoffmann-La Roche AG.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Amyotrophic Lateral Sclerosis
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Stem Cell Therapy
5.1.2 Medication
5.1.3 Others
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Mitsubishi Tanabe Pharma Corporation
6.1.2 Sun Pharmaceutical Industries Ltd.
6.1.3 CORESTEM, Inc
6.1.4 BrainStorm Cell Limited
6.1.5 Otsuka Pharmaceutical Co., Ltd.
6.1.6 AB Science
6.1.7 Ionis Pharmaceuticals
6.1.8 Biohaven Pharmaceutical
6.1.9 Biogen
6.1.10 F.Hoffmann-La Roche AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+